Glecirasib clinical trials
Also written JAB-21822.
How each study uses glecirasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the glecirasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
15 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 3
Allist Pharmaceuticals, Inc. (9) · Jian Li (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Abbisko Therapeutics Co, Ltd (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Sitneprotafib (2) · Izalontamab brengitecan (1) · Ivonescimab (1) · PD-L1 Inhibitor ABSK043 (1) · Sunvozertinib (1) · Crizotinib (1) · Pralsetinib (1) · Larotrectinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test glecirasib.
- Dec 2026A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.Phase 2 · Allist Pharmaceuticals, Inc.
- Mar 2027Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationPhase 1/2 · Allist Pharmaceuticals, Inc.
- Aug 2027A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1Phase 1/2 · Allist Pharmaceuticals, Inc.
- Sep 2027Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCPhase 1/2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses glecirasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07827261Written as Glecirasib
- A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1RecruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05276726Written as JAB 21822
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06416410Written as JAB-21822
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05288205Written as JAB-21822
- A Phase 2 Clinical Study of Combination Therapy With ABSK043 and GlecirasibRecruitingPhase 2Abbisko Therapeutics Co, LtdNCT07164170Written as ABSK043 in combination with Glecirasib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Glecirasib
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.RecruitingPhase 2Allist Pharmaceuticals, Inc.NCT06008288Written as JAB-21822
- Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07339839Written as Glecirasib
- A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaActive, not recruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05009329Written as JAB-21822
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive, not recruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05194995Written as JAB-21822
- JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C MutationCompletedPhase 1/2Jacobio Pharmaceuticals Co., Ltd.NCT05002270Written as JAB-21822 (KRAS G12C inhibitor)
- JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRCActive, not recruitingPhase 1Jian LiNCT06838338Written as JAB-21822
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy SubjectsCompletedPhase 1Allist Pharmaceuticals, Inc.NCT06162169Written as JAB-21822
- Mass Balance Study of [14C]JAB-21822CompletedPhase 1Allist Pharmaceuticals, Inc.NCT05920941Written as [14C]JAB-21822
- A Food Effect Study of JAB-21822 in Healthy SubjectsCompletedPhase 1Allist Pharmaceuticals, Inc.NCT05875493Written as JAB-21822
Codes
What other systems call glecirasib · ClinicalTrials.gg INT018156
- UNII (FDA) UP75WH4QKMGLECIRASIBOne source FDA
- NCI Thesaurus C181904GlecirasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UP75WH4QKM | GLECIRASIB | One source FDA |
| NCI Thesaurus | C181904 | Glecirasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.